Submission To Health Canada Essay

750 Words2 Pages

Intercept Pharma Canada files New Drug Submission to Health Canada for Marketing Approval of Obeticholic Acid for the Treatment of Patients with Primary Biliary Cholangitis

Obeticholic Acid represents first new treatment option for Primary Biliary Cholangitis in 20 years NEW YORK, NY, September 15, 2016 – Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced the filing of a New Drug Submission to Health Canada, seeking Canadian marketing approval for obeticholic acid (OCA) for the treatment of primary biliary cholangitis (PBC), when used in combination with ursodeoxycholic acid (UDCA) …show more content…

Mark Pruzanski, President & CEO of Intercept Pharmaceuticals. “We are pleased with Health Canada’s decision to grant OCA priority review status, recognizing the high unmet need in PBC patients, the potential of OCA to address that need, and the overall potential for significant improvements in care for these patients.

PBC is a rare, autoimmune cholestatic liver disease that puts patients at risk for life-threatening complications. PBC is primarily a disease of women, afflicting approximately one in 1,000 women over the age of 40; in Canada, this equates to roughly 8,000 cases across the country. If left untreated, survival of PBC patients is significantly worse than the general population.
Canadian expertise has played a significant role in driving both clinical research and advances in PBC care. With nine clinical trial sites across the country for PBC treatment, Canadian clinicians, patients and health institutions have been instrumental in PBC-related developments, including overall disease awareness and the development of …show more content…

Andrew Mason, Director of Research for the Division of Gastroenterology and Hepatology at the University of Alberta. “In the last few years, we’ve made a lot of progress in both understanding PBC and ensuring proper care for patients. With continued research and an emphasis on putting patients first, we look forward to the day where all PBC patients can truly manage their condition.

While Health Canada reviews the New Drug Submission, Intercept looks forward to engaging in Canada’s Common Drug Review process in parallel to enable access to Canadian PBC patients as soon as possible following potential regulatory approval.
In May 2016, OCA received accelerated approval from the US Food and Drug Administration and is currently under review with the European Medicines Agency (EMA).
About Obeticholic Acid (OCA)
Ocaliva is an agonist for FXR, a nuclear receptor expressed in the liver and intestine. FXR is a key regulator of bile acid, inflammatory, fibrotic, and metabolic pathways. If approved, OCA will offer an important new treatment option for the substantial number of patients who have an inadequate response to UDCA and are consequently at increased risk of liver failure, need for liver transplantation, or

More about Submission To Health Canada Essay

Open Document